• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Swedish study shows better glycemic control with continuous glucose monitoring

byDaniel FisherandMichael Milligan
January 27, 2017
in Chronic Disease, Endocrinology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Continuous glucose monitoring (CGM) more effectively lowered HbA1c and standard deviation of blood glucose than conventional therapy.

2. Subjective self-reports of well-being and satisfaction with treatment were increased among patients undergoing CGM than conventional therapy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Among patients with type 1 diabetes, careful blood glucose monitoring and intermittent insulin administration can achieve relatively tight glycemic control. As opposed to self-monitoring, wherein patients analyze their blood glucose and inject themselves manually with insulin, recent advances in technology have allowed for implantable devices that allow for continuous glucose monitoring (CGM). In this un-blinded, cross-over, randomized controlled trial conducted in Sweden, patients with poor glycemic control were randomized to receive 6 months of either conventional therapy or CGM followed by another 6 month period using the alternative therapy. CGM resulted in a significant decrease in HbA1c as well as standard deviation of blood glucose levels. In addition, patients relying on CGM reported improved levels of overall well-being, treatment satisfaction, and less fear of hypoglycemia. There was no difference in adverse events between groups.

This study suggests that CGM may be superior to conventional therapy for patients with poor glycemic control. However, more studies need to be performed to determine the effects of CGM in a broader patient populations, including those with good glycemic control particular comorbidities. In addition, a cost-benefit analysis between CGM and conventional therapy would greatly aid in the adoption of this technology.

Click to read the study in JAMA

Relevant Reading: Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data

RELATED REPORTS

Faricimab may improve visual acuity in patients with diabetic macular edema

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk

In-Depth [randomized controlled trial]: A total of 161 type 1 diabetics with HbA1c above 7.5% were randomly assigned to CGM or conventional therapy for 26 weeks, followed by a 17 week washout period, and then 26 weeks of the alternative therapy. At baseline, all patients used self-injection for insulin, as patients with insulin pumps were excluded. CGM reduced HbA1c by 0.43% (CI95 0.29 to 0.57%) more than conventional therapy. Likewise, CGM resulted in a lower blood glucose standard deviation (68.49 vs 77.34; p < 0.001). Patients who adhered to the CGM monitor protocol at least 70% of the time or more received benefit while those who didn’t were statistically similar to the conventional therapy group. CGM increased overall wellbeing (estimated by the WHO-5 66.1 vs 62.7; p = 0.02), and treatment satisfaction (Diabetes Satisfaction Questionnaire 30.21 vs 26.62; p < 0.001). It also reduced the fear of hypoglycemia (Hypoglycemia Confidence Questionnaire 3.40 vs 3.27; p < 0.001) compared to conventional therapy. No differences were found in the rate of adverse events.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: blood glucosediabetes mellitus
Previous Post

Bezlotoxumab associated with lower recurrence of C. difficile infection: The MODIFY I and II trials

Next Post

Improved glycemic control with continuous glucose monitoring in American diabetics

RelatedReports

Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

March 8, 2022
Insulin costs rose exponentially, regardless of formulation or patent
Cardiology

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

February 9, 2022
Cardiology

Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk

January 11, 2022
#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes
StudyGraphics

#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

December 2, 2021
Next Post
Pediatric DKA associated with recent acute care visits

Improved glycemic control with continuous glucose monitoring in American diabetics

Unenhanced magnetic resonance imaging highly sensitive and specific for acute appendicitis

External compression computed tomography may increase diagnostic accuracy in appendicitis

Researchers validate scoring of postconcussive symptom measure to characterize duration 

Researchers validate scoring of postconcussive symptom measure to characterize duration 

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.